A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: penetration (10), access (1000)

Docetaxel-Gemcitabine v1.2

Description
Chemotherapy Protocol SARCOMA DOCETAXEL-GEMCITABINE Regimen Sarcoma-Docetaxel-Gemcitabine Indication Relapsed metastatic osteosarcoma Selected metasta
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/Docetaxel-Gemcitabinev1.2.pdf

MyelomaPAD-Bortezomib(SC)DexamethasoneDoxorubicinVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA PAD (SC)-BORTEZOMIB (SC)-DEXAMETHASONE-DOXORUBICIN Regimen Multiple Myeloma – PAD (SC)-Bortezomi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibSCDexamethasoneDoxorubicinVer1.pdf

MyelomaPAD-Bortezomib(IV)DexamethasoneDoxorubicinVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA PAD (IV)-BORTEZOMIB (IV)-DEXAMETHASONE-DOXORUBICIN Regimen Multiple Myeloma – PAD (IV)-Bortezomi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibIVDexamethasoneDoxorubicinVer1.pdf

MyelomaMPVBortezomib(SC)MelphalanPrednisolone(35day)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA MPV (SC)-BORTEZOMIB (SC)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple Myeloma – MPV(SC)-Bortez
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibSCMelphalanPrednisolone35dayVer1.pdf

MyelomaMPVBortezomib(IV)MelphalanPrednisolone(35day)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA MPV (IV)-BORTEZOMIB (IV)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple Myeloma – MPV(IV)-Bortez
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibIVMelphalanPrednisolone35dayVer1.pdf

Lenalidomide

Description
Chemotherapy Protocol MULTIPLE MYELOMA LENALIDOMIDE Regimen • Multiple Myeloma – Lenalidomide Indication • Lenalidomide is recommended,
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Lenalidomide.pdf

Ipilimumab Ver 1

Description
Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisation, as an option fo
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf

Chlorambucil_7_Rituximab

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (7 day)-Rituximab Regimen • CLL – Chlorambucil (7 day)-Rituximab I
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-7-Rituximab.pdf

Chlorambucil_14_Rituximab

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (14 day)-Rituximab Regimen • CLL – Chlorambucil (14 day)-Rituximab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-14-Rituximab.pdf

Thyroid Cabozantinib

Description
Chemotherapy Protocol THYROID CANCER Regimen CABOZANTINIB • Thyroid – Cabozantinib (140mg-capsules) Indication • Unresectable, locally
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Thyroid-Cabozantinib.pdf
71 to 80 of 167
Previous … 6 7 8 9 10 … Next